{"gene":"BAD","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1997,"finding":"BAD is phosphorylated by the serine-threonine kinase Akt (PKB) downstream of IL-3/PI 3-kinase signaling, and this phosphorylation prevents BAD's pro-apoptotic function. Active Akt phosphorylated BAD in vivo and in vitro at the same residues phosphorylated in response to IL-3.","method":"In vitro kinase assay, in vivo phosphorylation analysis with PI 3-kinase inhibitors, IL-3-stimulated cell assays","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase reconstitution plus in vivo validation, independently replicated and widely cited as foundational mechanism","pmids":["9381178"],"is_preprint":false},{"year":2000,"finding":"Phosphorylation of BAD at Ser-155 within its BH3 domain (by PKA, RSK1, and survival factor signaling) blocks BAD binding to Bcl-XL, providing a second phosphorylation-dependent mechanism to inhibit BAD's death-promoting activity, distinct from Ser-112/Ser-136 phosphorylation that promotes 14-3-3 binding. RSK1 phosphorylates BAD at both Ser-112 and Ser-155 and rescues BAD-mediated cell death in a manner dependent on phosphorylation at both sites.","method":"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, cell death rescue assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro kinase assay with mutagenesis and co-IP in a single focused study with multiple orthogonal methods","pmids":["10837486"],"is_preprint":false},{"year":2006,"finding":"Tuberin (TSC2) activates the pro-apoptotic function of BAD by reducing phosphorylation of BAD at Ser136 (via downregulation of p70S6K activity) and upregulating BAD/BCL-2 and BAD/BCL-XL heterodimerization, thereby promoting apoptosis. BAD-knockout cells confirmed BAD is required as a mediator of tuberin's apoptotic effects.","method":"BAD-/- cell experiments, co-immunoprecipitation (BAD/BCL-2 and BAD/BCL-XL interaction), phosphorylation analysis, overexpression/knockdown of TSC2","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with genetic KO validation and phosphorylation analysis, single lab with multiple orthogonal approaches","pmids":["16702951"],"is_preprint":false},{"year":2008,"finding":"BAD functions as a BH3-only pro-apoptotic protein that is regulated by post-translational phosphorylation at multiple serine residues by survival kinases; phosphorylation sequesters BAD to 14-3-3 proteins away from mitochondria, while unphosphorylated BAD heterodimerizes with BCL-2/BCL-XL at the mitochondrial membrane to promote apoptosis. BAD also participates in non-apoptotic roles in glucose metabolism, coordinating mitochondrial fuel metabolism with the apoptotic machinery.","method":"Review synthesizing biochemical studies and genetic models (BAD knockout mice)","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Strong — synthesis of multiple experimental studies; mechanistic framework supported by genetic models and biochemical reconstitution across labs","pmids":["19641507"],"is_preprint":false},{"year":2002,"finding":"BAD provides a genetic link between the cell death machinery and survival signaling pathways in vivo, as demonstrated in Drosophila and mammalian genetic studies showing BAD's role in connecting survival kinase signaling to the apoptotic machinery.","method":"Genetic epistasis and in vivo studies in model organisms","journal":"Developmental Cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis in vivo; commentary synthesizing experimental findings on BAD pathway placement","pmids":["12431365"],"is_preprint":false},{"year":2015,"finding":"BAD phosphorylation at serine residues (human S75, S99, and S118) determines whether BAD acts pro-apoptotically or pro-survival, and pBAD protein levels are higher in cancer cells compared to immortalized normal cells; depletion of the phosphatase PP2C increases pBAD levels and confers a growth advantage, implicating the BAD phosphorylation state in cancer cell survival.","method":"siRNA depletion of PP2C, MTS proliferation assays, immunofluorescence for pBAD, RT-qPCR for PP2C","journal":"International Journal of Molecular Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional siRNA knockdown with defined cellular phenotype and phosphorylation mechanistic follow-up, single lab","pmids":["25653146"],"is_preprint":false},{"year":2017,"finding":"BAD phosphorylation at three specific serine residues (human S75, S99, S118) regulates its dual role as pro-apoptotic or pro-survival protein; phosphorylated BAD also has non-apoptotic functions including regulation of glycolysis, autophagy, and cell cycle progression.","method":"Review synthesizing in vitro and in vivo experimental findings on BAD phosphorylation","journal":"Cancer Letters","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — review article synthesizing prior experimental data; no new primary experiments reported","pmids":["29175460"],"is_preprint":false}],"current_model":"BAD is a BH3-only pro-apoptotic BCL-2 family member that is held inactive through phosphorylation at multiple serine residues (Ser-112, Ser-136, Ser-155 in mouse; S75, S99, S118 in human) by survival kinases including Akt (downstream of IL-3/PI 3-kinase), PKA, and RSK1; phosphorylation at Ser-112/136 sequesters BAD to cytoplasmic 14-3-3 proteins, while phosphorylation at Ser-155 within the BH3 domain directly blocks heterodimerization with BCL-XL, and unphosphorylated BAD localizes to mitochondria where it binds BCL-2/BCL-XL to promote apoptosis; BAD is also dephosphorylated/activated downstream of the TSC2 tumor suppressor, and beyond apoptosis BAD participates in regulating glucose metabolism at the mitochondria."},"narrative":{"mechanistic_narrative":"BAD is a BH3-only pro-apoptotic BCL-2 family member that couples survival-kinase signaling to the mitochondrial apoptotic machinery, with its activity gated by multisite serine phosphorylation [PMID:9381178, PMID:19641507, PMID:12431365]. In its unphosphorylated state, BAD localizes to mitochondria and heterodimerizes with the anti-apoptotic proteins BCL-2 and BCL-XL to promote cell death, whereas phosphorylation sequesters it away from mitochondria via 14-3-3 binding and neutralizes its death-promoting function [PMID:19641507]. Survival signaling enforces this inhibition through several kinases: Akt phosphorylates BAD downstream of IL-3/PI 3-kinase to block its pro-apoptotic activity [PMID:9381178], while PKA and RSK1 phosphorylate Ser-155 within the BH3 domain to directly disrupt BAD–BCL-XL binding, a mechanism distinct from the Ser-112/Ser-136 phosphorylation that drives 14-3-3 sequestration [PMID:10837486]. Conversely, the TSC2 tumor suppressor activates BAD by reducing Ser-136 phosphorylation through downregulation of p70S6K, increasing BAD/BCL-2 and BAD/BCL-XL heterodimerization to promote apoptosis [PMID:16702951]. The balance of BAD phosphorylation (human S75, S99, S118) sets the pro-apoptotic versus pro-survival output, and dephosphorylation by PP2C-class phosphatases opposes the survival state; elevated phospho-BAD confers a growth advantage in cancer cells [PMID:25653146]. Beyond apoptosis, BAD participates in non-apoptotic functions including the regulation of mitochondrial glucose metabolism [PMID:19641507].","teleology":[{"year":1997,"claim":"Established that survival signaling directly inactivates the death machinery by identifying Akt as the kinase that phosphorylates BAD downstream of IL-3/PI 3-kinase, linking growth-factor signaling to apoptosis suppression.","evidence":"In vitro kinase reconstitution plus in vivo phosphorylation analysis with PI 3-kinase inhibitors in IL-3-stimulated cells","pmids":["9381178"],"confidence":"High","gaps":["Did not resolve how phosphorylation translates to subcellular relocalization away from mitochondria","Other survival kinases acting on BAD not yet mapped"]},{"year":2000,"claim":"Resolved that BAD inhibition occurs through two mechanistically distinct phosphorylation modes, showing that Ser-155 phosphorylation within the BH3 domain directly blocks BCL-XL binding, separate from the Ser-112/Ser-136 sites that drive 14-3-3 sequestration.","evidence":"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, and cell death rescue assays with PKA and RSK1","pmids":["10837486"],"confidence":"High","gaps":["Relative contribution of each site to physiological survival signaling not quantified","Structural basis of BH3-domain phosphorylation blocking heterodimerization not determined"]},{"year":2002,"claim":"Placed BAD genetically as the connector between survival kinase signaling and the apoptotic machinery in vivo, validating its pathway position across model organisms.","evidence":"Genetic epistasis and in vivo studies in Drosophila and mammals","pmids":["12431365"],"confidence":"Medium","gaps":["Commentary-level synthesis rather than a single primary mechanistic dataset","Did not define tissue-specific kinase inputs"]},{"year":2006,"claim":"Identified an upstream activator of BAD by showing the TSC2 tumor suppressor reduces Ser-136 phosphorylation via p70S6K downregulation and increases BAD/BCL-2 and BAD/BCL-XL heterodimerization to drive apoptosis.","evidence":"BAD-/- cell experiments, reciprocal co-immunoprecipitation, phosphorylation analysis, and TSC2 overexpression/knockdown","pmids":["16702951"],"confidence":"Medium","gaps":["Phosphatase mediating the Ser-136 dephosphorylation not identified","Single-lab study with limited cell-type breadth"]},{"year":2015,"claim":"Linked the BAD phosphorylation state to cancer cell survival by showing phospho-BAD is elevated in cancer cells and that PP2C depletion further raises phospho-BAD and confers a growth advantage.","evidence":"siRNA depletion of PP2C, MTS proliferation assays, immunofluorescence for phospho-BAD, RT-qPCR","pmids":["25653146"],"confidence":"Medium","gaps":["Direct phosphatase–substrate relationship between PP2C and BAD not biochemically reconstituted","Specific PP2C isoform and target residues not pinpointed"]},{"year":2017,"claim":"Consolidated the model that three serine phosphosites (S75, S99, S118) toggle BAD between pro-apoptotic and pro-survival functions, including non-apoptotic roles in glycolysis, autophagy, and cell cycle.","evidence":"Review synthesizing prior in vitro and in vivo phosphorylation studies","pmids":["29175460"],"confidence":"Low","gaps":["Review without new primary experiments","Molecular mechanisms underlying the non-apoptotic glycolytic and autophagy roles not detailed"]},{"year":null,"claim":"How BAD mechanistically coordinates mitochondrial glucose metabolism with the apoptotic decision, and which phosphatases physiologically reactivate BAD, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No reconstituted mechanism connecting BAD phosphorylation to metabolic enzyme activity","Physiological phosphatase(s) reactivating BAD in vivo not definitively established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,3]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,3,4]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,2]}],"complexes":[],"partners":["BCL2","BCL2L1","AKT1","RSK1","PRKACA","TSC2","YWHAZ"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q92934","full_name":"Bcl2-associated agonist of cell death","aliases":["Bcl-2-binding component 6","Bcl-2-like protein 8","Bcl2-L-8","Bcl-xL/Bcl-2-associated death promoter","Bcl2 antagonist of cell death"],"length_aa":168,"mass_kda":18.4,"function":"Promotes cell death. Successfully competes for the binding to Bcl-X(L), Bcl-2 and Bcl-W, thereby affecting the level of heterodimerization of these proteins with BAX. Can reverse the death repressor activity of Bcl-X(L), but not that of Bcl-2 (By similarity). Appears to act as a link between growth factor receptor signaling and the apoptotic pathways","subcellular_location":"Mitochondrion outer membrane; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q92934/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BAD","classification":"Not Classified","n_dependent_lines":36,"n_total_lines":1208,"dependency_fraction":0.029801324503311258},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BAD","total_profiled":1310},"omim":[{"mim_id":"619894","title":"ABHYDROLASE DOMAIN-CONTAINING PROTEIN 15; ABHD15","url":"https://www.omim.org/entry/619894"},{"mim_id":"618148","title":"EXTRAORAL HALITOSIS DUE TO METHANETHIOL OXIDASE DEFICIENCY; EHMTO","url":"https://www.omim.org/entry/618148"},{"mim_id":"616349","title":"SORBIN AND SH3 DOMAINS-CONTAINING PROTEIN 2; SORBS2","url":"https://www.omim.org/entry/616349"},{"mim_id":"615736","title":"ENDOTHELIAL CELL SURFACE-EXPRESSED CHEMOTAXIS AND APOPTOSIS REGULATOR; ECSCR","url":"https://www.omim.org/entry/615736"},{"mim_id":"614641","title":"LYSOSOME-ASSOCIATED MEMBRANE PROTEIN 5; LAMP5","url":"https://www.omim.org/entry/614641"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Mitochondria","reliability":"Enhanced"},{"location":"Principal piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BAD"},"hgnc":{"alias_symbol":["BCL2L8","BBC2"],"prev_symbol":[]},"alphafold":{"accession":"Q92934","domains":[{"cath_id":"1.20.5","chopping":"101-125","consensus_level":"medium","plddt":81.4544,"start":101,"end":125}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92934","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q92934-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q92934-F1-predicted_aligned_error_v6.png","plddt_mean":60.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BAD","jax_strain_url":"https://www.jax.org/strain/search?query=BAD"},"sequence":{"accession":"Q92934","fasta_url":"https://rest.uniprot.org/uniprotkb/Q92934.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q92934/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q92934"}},"corpus_meta":[{"pmid":"17667954","id":"PMC_17667954","title":"Cellular senescence: when bad things happen to good cells.","date":"2007","source":"Nature reviews. Molecular cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/17667954","citation_count":3490,"is_preprint":false},{"pmid":"9381178","id":"PMC_9381178","title":"Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt.","date":"1997","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9381178","citation_count":1808,"is_preprint":false},{"pmid":"23652116","id":"PMC_23652116","title":"PPARγ signaling and metabolism: the good, the bad and the future.","date":"2013","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23652116","citation_count":1625,"is_preprint":false},{"pmid":"10481183","id":"PMC_10481183","title":"Stress and cognition: are corticosteroids good or bad guys?","date":"1999","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/10481183","citation_count":922,"is_preprint":false},{"pmid":"35922662","id":"PMC_35922662","title":"Cellular senescence: the good, the bad and the unknown.","date":"2022","source":"Nature reviews. Nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/35922662","citation_count":890,"is_preprint":false},{"pmid":"20302969","id":"PMC_20302969","title":"Preservatives in eyedrops: the good, the bad and the ugly.","date":"2010","source":"Progress in retinal and eye research","url":"https://pubmed.ncbi.nlm.nih.gov/20302969","citation_count":793,"is_preprint":false},{"pmid":"26342753","id":"PMC_26342753","title":"Microglia in the TBI brain: The good, the bad, and the dysregulated.","date":"2015","source":"Experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/26342753","citation_count":602,"is_preprint":false},{"pmid":"22883509","id":"PMC_22883509","title":"Diabetes and hypertension: the bad companions.","date":"2012","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/22883509","citation_count":497,"is_preprint":false},{"pmid":"23723299","id":"PMC_23723299","title":"HMGB1 in cancer: good, bad, or both?","date":"2013","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/23723299","citation_count":417,"is_preprint":false},{"pmid":"18285820","id":"PMC_18285820","title":"DNA-damage repair; the good, the bad, and the ugly.","date":"2008","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/18285820","citation_count":377,"is_preprint":false},{"pmid":"34456917","id":"PMC_34456917","title":"Macrophages: The Good, the Bad, and the Gluttony.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34456917","citation_count":343,"is_preprint":false},{"pmid":"26045257","id":"PMC_26045257","title":"Breaking bad: R-loops and genome integrity.","date":"2015","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/26045257","citation_count":290,"is_preprint":false},{"pmid":"19731042","id":"PMC_19731042","title":"Microglia in ALS: the good, the bad, and the resting.","date":"2009","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/19731042","citation_count":274,"is_preprint":false},{"pmid":"10837486","id":"PMC_10837486","title":"BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10837486","citation_count":272,"is_preprint":false},{"pmid":"20837599","id":"PMC_20837599","title":"EpCAM in carcinogenesis: the good, the bad or the ugly.","date":"2010","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/20837599","citation_count":257,"is_preprint":false},{"pmid":"26631912","id":"PMC_26631912","title":"The good and the bad faces of STAT1 in solid tumours.","date":"2015","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/26631912","citation_count":227,"is_preprint":false},{"pmid":"20079660","id":"PMC_20079660","title":"Prostaglandins in bone: bad cop, good cop?","date":"2010","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/20079660","citation_count":220,"is_preprint":false},{"pmid":"19641507","id":"PMC_19641507","title":"BAD: undertaker by night, candyman by day.","date":"2008","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/19641507","citation_count":214,"is_preprint":false},{"pmid":"20813183","id":"PMC_20813183","title":"RNA granules: the good, the bad and the ugly.","date":"2010","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/20813183","citation_count":211,"is_preprint":false},{"pmid":"12150992","id":"PMC_12150992","title":"p53: good cop/bad cop.","date":"2002","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/12150992","citation_count":204,"is_preprint":false},{"pmid":"26719327","id":"PMC_26719327","title":"Amyloid-β Receptors: The Good, the Bad, and the Prion Protein.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26719327","citation_count":203,"is_preprint":false},{"pmid":"26588930","id":"PMC_26588930","title":"Protoporphyrin IX: the Good, the Bad, and the Ugly.","date":"2015","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/26588930","citation_count":186,"is_preprint":false},{"pmid":"28754468","id":"PMC_28754468","title":"Microhomology-mediated end joining: Good, bad and ugly.","date":"2017","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/28754468","citation_count":176,"is_preprint":false},{"pmid":"12765839","id":"PMC_12765839","title":"Does Rap1 deserve a bad Rap?","date":"2003","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/12765839","citation_count":171,"is_preprint":false},{"pmid":"28651238","id":"PMC_28651238","title":"Inducible nitric oxide synthase: Good or bad?","date":"2017","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/28651238","citation_count":166,"is_preprint":false},{"pmid":"26593532","id":"PMC_26593532","title":"Understanding genistein in cancer: The \"good\" and the \"bad\" effects: A review.","date":"2015","source":"Food chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26593532","citation_count":166,"is_preprint":false},{"pmid":"32819363","id":"PMC_32819363","title":"Insulin: too much of a good thing is bad.","date":"2020","source":"BMC medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32819363","citation_count":164,"is_preprint":false},{"pmid":"14672753","id":"PMC_14672753","title":"Herbal bioactivation: the good, the bad and the ugly.","date":"2004","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/14672753","citation_count":162,"is_preprint":false},{"pmid":"24698494","id":"PMC_24698494","title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis.","date":"2014","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/24698494","citation_count":156,"is_preprint":false},{"pmid":"31495461","id":"PMC_31495461","title":"The Good and the Bad of Mitochondrial Breakups.","date":"2019","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31495461","citation_count":150,"is_preprint":false},{"pmid":"11816794","id":"PMC_11816794","title":"Dysregulation of cellular calcium homeostasis in Alzheimer's disease: bad genes and bad habits.","date":"2001","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/11816794","citation_count":145,"is_preprint":false},{"pmid":"24774301","id":"PMC_24774301","title":"Good guy or bad guy: the opposing roles of microRNA 125b in cancer.","date":"2014","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/24774301","citation_count":142,"is_preprint":false},{"pmid":"26528864","id":"PMC_26528864","title":"Antibiotic prophylaxis in cirrhosis: Good and bad.","date":"2016","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26528864","citation_count":141,"is_preprint":false},{"pmid":"26358502","id":"PMC_26358502","title":"HSP90AB1: Helping the good and the bad.","date":"2015","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/26358502","citation_count":140,"is_preprint":false},{"pmid":"26075331","id":"PMC_26075331","title":"Ketamine and phencyclidine: the good, the bad and the unexpected.","date":"2015","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26075331","citation_count":138,"is_preprint":false},{"pmid":"29567370","id":"PMC_29567370","title":"Endoreplication: The Good, the Bad, and the Ugly.","date":"2018","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29567370","citation_count":134,"is_preprint":false},{"pmid":"20830700","id":"PMC_20830700","title":"Acyl glucuronides: the good, the bad and the ugly.","date":"2010","source":"Biopharmaceutics & drug disposition","url":"https://pubmed.ncbi.nlm.nih.gov/20830700","citation_count":131,"is_preprint":false},{"pmid":"34953942","id":"PMC_34953942","title":"Vimentin and cytokeratin: Good alone, bad together.","date":"2021","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/34953942","citation_count":126,"is_preprint":false},{"pmid":"26706755","id":"PMC_26706755","title":"Suicide and sleep: Is it a bad thing to be awake when reason sleeps?","date":"2015","source":"Sleep medicine reviews","url":"https://pubmed.ncbi.nlm.nih.gov/26706755","citation_count":126,"is_preprint":false},{"pmid":"11313715","id":"PMC_11313715","title":"Baculoviruses and apoptosis: the good, the bad, and the ugly.","date":"2001","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/11313715","citation_count":123,"is_preprint":false},{"pmid":"34082816","id":"PMC_34082816","title":"Losing DNA methylation at repetitive elements and breaking bad.","date":"2021","source":"Epigenetics & chromatin","url":"https://pubmed.ncbi.nlm.nih.gov/34082816","citation_count":114,"is_preprint":false},{"pmid":"30510918","id":"PMC_30510918","title":"Breaking Bad: How Viruses Subvert the Cell Cycle.","date":"2018","source":"Frontiers in cellular and infection microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/30510918","citation_count":113,"is_preprint":false},{"pmid":"31295858","id":"PMC_31295858","title":"Autophagy in Neurotrauma: Good, Bad, or Dysregulated.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31295858","citation_count":108,"is_preprint":false},{"pmid":"16929174","id":"PMC_16929174","title":"REST in good times and bad: roles in tumor suppressor and oncogenic activities.","date":"2006","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/16929174","citation_count":107,"is_preprint":false},{"pmid":"11817325","id":"PMC_11817325","title":"Sepsis-induced immunosuppression: from bad to worse.","date":"2001","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/11817325","citation_count":105,"is_preprint":false},{"pmid":"28825357","id":"PMC_28825357","title":"Multinucleated Giant Cells: Good Guys or Bad Guys?","date":"2017","source":"Tissue engineering. Part B, Reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28825357","citation_count":104,"is_preprint":false},{"pmid":"28462521","id":"PMC_28462521","title":"RIPK3 in cell death and inflammation: the good, the bad, and the ugly.","date":"2017","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/28462521","citation_count":103,"is_preprint":false},{"pmid":"28149296","id":"PMC_28149296","title":"STATs in NK-Cells: The Good, the Bad, and the Ugly.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28149296","citation_count":101,"is_preprint":false},{"pmid":"16023855","id":"PMC_16023855","title":"Aneuploidy: a matter of bad connections.","date":"2005","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/16023855","citation_count":100,"is_preprint":false},{"pmid":"28502781","id":"PMC_28502781","title":"Checks and balances: The glucocorticoid receptor and NFĸB in good times and bad.","date":"2017","source":"Frontiers in neuroendocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/28502781","citation_count":99,"is_preprint":false},{"pmid":"34356112","id":"PMC_34356112","title":"Hydroxyurea-The Good, the Bad and the Ugly.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/34356112","citation_count":96,"is_preprint":false},{"pmid":"19222802","id":"PMC_19222802","title":"The good and the bad of chemokines/chemokine receptors in melanoma.","date":"2009","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/19222802","citation_count":95,"is_preprint":false},{"pmid":"32113062","id":"PMC_32113062","title":"Ethanol metabolism: The good, the bad, and the ugly.","date":"2020","source":"Medical hypotheses","url":"https://pubmed.ncbi.nlm.nih.gov/32113062","citation_count":91,"is_preprint":false},{"pmid":"39255773","id":"PMC_39255773","title":"Classifying cancer-associated fibroblasts-The good, the bad, and the target.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/39255773","citation_count":90,"is_preprint":false},{"pmid":"26150063","id":"PMC_26150063","title":"When Too Much ATP Is Bad for Protein Synthesis.","date":"2015","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/26150063","citation_count":90,"is_preprint":false},{"pmid":"31843970","id":"PMC_31843970","title":"The balancing act of R-loop biology: The good, the bad, and the ugly.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31843970","citation_count":90,"is_preprint":false},{"pmid":"23396454","id":"PMC_23396454","title":"Pathogenic arterial remodeling: the good and bad of microRNAs.","date":"2013","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/23396454","citation_count":89,"is_preprint":false},{"pmid":"31558857","id":"PMC_31558857","title":"Hepatic senescence, the good and the bad.","date":"2019","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/31558857","citation_count":86,"is_preprint":false},{"pmid":"31248787","id":"PMC_31248787","title":"Quiescence: Good and Bad of Stem Cell Aging.","date":"2019","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31248787","citation_count":80,"is_preprint":false},{"pmid":"26366975","id":"PMC_26366975","title":"Minireview: Were the IGF Signaling Inhibitors All Bad?","date":"2015","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26366975","citation_count":79,"is_preprint":false},{"pmid":"20980638","id":"PMC_20980638","title":"Is soy consumption good or bad for the breast?","date":"2010","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/20980638","citation_count":78,"is_preprint":false},{"pmid":"24592259","id":"PMC_24592259","title":"Inclusion bodies: not that bad….","date":"2014","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/24592259","citation_count":77,"is_preprint":false},{"pmid":"12431365","id":"PMC_12431365","title":"Survival signaling goes BAD.","date":"2002","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/12431365","citation_count":77,"is_preprint":false},{"pmid":"29157973","id":"PMC_29157973","title":"When the good go bad: Mutant NPM1 in acute myeloid leukemia.","date":"2017","source":"Blood reviews","url":"https://pubmed.ncbi.nlm.nih.gov/29157973","citation_count":75,"is_preprint":false},{"pmid":"36409792","id":"PMC_36409792","title":"NRF2 and Diabetes: The Good, the Bad, and the Complex.","date":"2022","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/36409792","citation_count":74,"is_preprint":false},{"pmid":"27500281","id":"PMC_27500281","title":"Interferons and HIV Infection: The Good, the Bad, and the Ugly.","date":"2016","source":"Pathogens & immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27500281","citation_count":72,"is_preprint":false},{"pmid":"29288743","id":"PMC_29288743","title":"The good and bad faces of the CXCR4 chemokine receptor.","date":"2017","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29288743","citation_count":70,"is_preprint":false},{"pmid":"29359811","id":"PMC_29359811","title":"Rubisco is not really so bad.","date":"2018","source":"Plant, cell & environment","url":"https://pubmed.ncbi.nlm.nih.gov/29359811","citation_count":70,"is_preprint":false},{"pmid":"29175460","id":"PMC_29175460","title":"Bad phosphorylation as a target of inhibition in oncology.","date":"2017","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29175460","citation_count":68,"is_preprint":false},{"pmid":"28986960","id":"PMC_28986960","title":"Bad wrap: Myelin and myelin plasticity in health and disease.","date":"2017","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28986960","citation_count":67,"is_preprint":false},{"pmid":"29802200","id":"PMC_29802200","title":"RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer's disease.","date":"2018","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29802200","citation_count":66,"is_preprint":false},{"pmid":"17371265","id":"PMC_17371265","title":"Inflammation and polyamine catabolism: the good, the bad and the ugly.","date":"2007","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/17371265","citation_count":65,"is_preprint":false},{"pmid":"17572303","id":"PMC_17572303","title":"Amplification of zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.","date":"2007","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17572303","citation_count":65,"is_preprint":false},{"pmid":"27890469","id":"PMC_27890469","title":"Methamphetamine Addiction Vulnerability: The Glutamate, the Bad, and the Ugly.","date":"2016","source":"Biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27890469","citation_count":65,"is_preprint":false},{"pmid":"25645467","id":"PMC_25645467","title":"Aging and radiation: bad companions.","date":"2015","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/25645467","citation_count":62,"is_preprint":false},{"pmid":"27194720","id":"PMC_27194720","title":"Hippo signaling in the kidney: the good and the bad.","date":"2016","source":"American journal of physiology. Renal physiology","url":"https://pubmed.ncbi.nlm.nih.gov/27194720","citation_count":60,"is_preprint":false},{"pmid":"25198129","id":"PMC_25198129","title":"Clostridium and bacillus binary enterotoxins: bad for the bowels, and eukaryotic being.","date":"2014","source":"Toxins","url":"https://pubmed.ncbi.nlm.nih.gov/25198129","citation_count":60,"is_preprint":false},{"pmid":"26330289","id":"PMC_26330289","title":"Premature aging/senescence in cancer cells facing therapy: good or bad?","date":"2015","source":"Biogerontology","url":"https://pubmed.ncbi.nlm.nih.gov/26330289","citation_count":57,"is_preprint":false},{"pmid":"17001680","id":"PMC_17001680","title":"Galactosemia: the good, the bad, and the unknown.","date":"2006","source":"Journal of cellular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17001680","citation_count":56,"is_preprint":false},{"pmid":"35965328","id":"PMC_35965328","title":"The diverse functions of FAT1 in cancer progression: good, bad, or ugly?","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35965328","citation_count":51,"is_preprint":false},{"pmid":"28174746","id":"PMC_28174746","title":"The Farnesoid X Receptor: Good for BAD.","date":"2016","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/28174746","citation_count":50,"is_preprint":false},{"pmid":"30299886","id":"PMC_30299886","title":"MECHANISMS IN ENDOCRINOLOGY: Bone marrow adiposity and bone, a bad romance?","date":"2018","source":"European journal of endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/30299886","citation_count":50,"is_preprint":false},{"pmid":"22619696","id":"PMC_22619696","title":"The bad, the good, and the ugly about oxidative stress.","date":"2012","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/22619696","citation_count":49,"is_preprint":false},{"pmid":"19519406","id":"PMC_19519406","title":"The TRAIL to viral pathogenesis: the good, the bad and the ugly.","date":"2009","source":"Current molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19519406","citation_count":48,"is_preprint":false},{"pmid":"31293374","id":"PMC_31293374","title":"Tau Secretion: Good and Bad for Neurons.","date":"2019","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/31293374","citation_count":47,"is_preprint":false},{"pmid":"25698357","id":"PMC_25698357","title":"The good and bad of antioxidant foods: An immunological perspective.","date":"2015","source":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","url":"https://pubmed.ncbi.nlm.nih.gov/25698357","citation_count":47,"is_preprint":false},{"pmid":"36854316","id":"PMC_36854316","title":"Circadian Rhythms and Astrocytes: The Good, the Bad, and the Ugly.","date":"2023","source":"Annual review of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36854316","citation_count":46,"is_preprint":false},{"pmid":"25653146","id":"PMC_25653146","title":"BAD-mediated apoptotic pathway is associated with human cancer development.","date":"2015","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25653146","citation_count":46,"is_preprint":false},{"pmid":"23305486","id":"PMC_23305486","title":"Wrapping up the bad news: HIV assembly and release.","date":"2013","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/23305486","citation_count":45,"is_preprint":false},{"pmid":"29109232","id":"PMC_29109232","title":"Recombination: the good, the bad and the variable.","date":"2017","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29109232","citation_count":44,"is_preprint":false},{"pmid":"16702951","id":"PMC_16702951","title":"Tuberin activates the proapoptotic molecule BAD.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16702951","citation_count":44,"is_preprint":false},{"pmid":"10203801","id":"PMC_10203801","title":"Mitochondrial DNA--all things bad?","date":"1999","source":"Trends in genetics : TIG","url":"https://pubmed.ncbi.nlm.nih.gov/10203801","citation_count":43,"is_preprint":false},{"pmid":"34206333","id":"PMC_34206333","title":"Pterygium-The Good, the Bad, and the Ugly.","date":"2021","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/34206333","citation_count":42,"is_preprint":false},{"pmid":"34982579","id":"PMC_34982579","title":"Plant-Based Proteins: The Good, Bad, and Ugly.","date":"2022","source":"Annual review of food science and technology","url":"https://pubmed.ncbi.nlm.nih.gov/34982579","citation_count":42,"is_preprint":false},{"pmid":"24238608","id":"PMC_24238608","title":"Sperm mitochondria in reproduction: good or bad and where do they go?","date":"2013","source":"Journal of genetics and genomics = Yi chuan xue bao","url":"https://pubmed.ncbi.nlm.nih.gov/24238608","citation_count":42,"is_preprint":false},{"pmid":"35202786","id":"PMC_35202786","title":"Good, bad, and neglectful: Astrocyte changes in neurodegenerative disease.","date":"2022","source":"Free radical biology & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35202786","citation_count":41,"is_preprint":false},{"pmid":"18262406","id":"PMC_18262406","title":"Senescence: the good the bad and the dysfunctional.","date":"2008","source":"Current opinion in genetics & development","url":"https://pubmed.ncbi.nlm.nih.gov/18262406","citation_count":41,"is_preprint":false},{"pmid":"34139275","id":"PMC_34139275","title":"Consequence of distinctive expression of MUC2 in colorectal cancers: How much is actually bad?","date":"2021","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/34139275","citation_count":39,"is_preprint":false},{"pmid":"32429417","id":"PMC_32429417","title":"The Good, the Bad, the Question-H19 in Hepatocellular Carcinoma.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/32429417","citation_count":38,"is_preprint":false},{"pmid":"18583938","id":"PMC_18583938","title":"In good times and bad: p73 in cancer.","date":"2008","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/18583938","citation_count":38,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":38084,"output_tokens":1897,"usd":0.071354,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8809,"output_tokens":2618,"usd":0.054747,"stage2_stop_reason":"end_turn"},"total_usd":0.126101,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"BAD is phosphorylated by the serine-threonine kinase Akt (PKB) downstream of IL-3/PI 3-kinase signaling, and this phosphorylation prevents BAD's pro-apoptotic function. Active Akt phosphorylated BAD in vivo and in vitro at the same residues phosphorylated in response to IL-3.\",\n      \"method\": \"In vitro kinase assay, in vivo phosphorylation analysis with PI 3-kinase inhibitors, IL-3-stimulated cell assays\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase reconstitution plus in vivo validation, independently replicated and widely cited as foundational mechanism\",\n      \"pmids\": [\"9381178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Phosphorylation of BAD at Ser-155 within its BH3 domain (by PKA, RSK1, and survival factor signaling) blocks BAD binding to Bcl-XL, providing a second phosphorylation-dependent mechanism to inhibit BAD's death-promoting activity, distinct from Ser-112/Ser-136 phosphorylation that promotes 14-3-3 binding. RSK1 phosphorylates BAD at both Ser-112 and Ser-155 and rescues BAD-mediated cell death in a manner dependent on phosphorylation at both sites.\",\n      \"method\": \"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, cell death rescue assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro kinase assay with mutagenesis and co-IP in a single focused study with multiple orthogonal methods\",\n      \"pmids\": [\"10837486\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Tuberin (TSC2) activates the pro-apoptotic function of BAD by reducing phosphorylation of BAD at Ser136 (via downregulation of p70S6K activity) and upregulating BAD/BCL-2 and BAD/BCL-XL heterodimerization, thereby promoting apoptosis. BAD-knockout cells confirmed BAD is required as a mediator of tuberin's apoptotic effects.\",\n      \"method\": \"BAD-/- cell experiments, co-immunoprecipitation (BAD/BCL-2 and BAD/BCL-XL interaction), phosphorylation analysis, overexpression/knockdown of TSC2\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with genetic KO validation and phosphorylation analysis, single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"16702951\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"BAD functions as a BH3-only pro-apoptotic protein that is regulated by post-translational phosphorylation at multiple serine residues by survival kinases; phosphorylation sequesters BAD to 14-3-3 proteins away from mitochondria, while unphosphorylated BAD heterodimerizes with BCL-2/BCL-XL at the mitochondrial membrane to promote apoptosis. BAD also participates in non-apoptotic roles in glucose metabolism, coordinating mitochondrial fuel metabolism with the apoptotic machinery.\",\n      \"method\": \"Review synthesizing biochemical studies and genetic models (BAD knockout mice)\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Strong — synthesis of multiple experimental studies; mechanistic framework supported by genetic models and biochemical reconstitution across labs\",\n      \"pmids\": [\"19641507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"BAD provides a genetic link between the cell death machinery and survival signaling pathways in vivo, as demonstrated in Drosophila and mammalian genetic studies showing BAD's role in connecting survival kinase signaling to the apoptotic machinery.\",\n      \"method\": \"Genetic epistasis and in vivo studies in model organisms\",\n      \"journal\": \"Developmental Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis in vivo; commentary synthesizing experimental findings on BAD pathway placement\",\n      \"pmids\": [\"12431365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BAD phosphorylation at serine residues (human S75, S99, and S118) determines whether BAD acts pro-apoptotically or pro-survival, and pBAD protein levels are higher in cancer cells compared to immortalized normal cells; depletion of the phosphatase PP2C increases pBAD levels and confers a growth advantage, implicating the BAD phosphorylation state in cancer cell survival.\",\n      \"method\": \"siRNA depletion of PP2C, MTS proliferation assays, immunofluorescence for pBAD, RT-qPCR for PP2C\",\n      \"journal\": \"International Journal of Molecular Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional siRNA knockdown with defined cellular phenotype and phosphorylation mechanistic follow-up, single lab\",\n      \"pmids\": [\"25653146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BAD phosphorylation at three specific serine residues (human S75, S99, S118) regulates its dual role as pro-apoptotic or pro-survival protein; phosphorylated BAD also has non-apoptotic functions including regulation of glycolysis, autophagy, and cell cycle progression.\",\n      \"method\": \"Review synthesizing in vitro and in vivo experimental findings on BAD phosphorylation\",\n      \"journal\": \"Cancer Letters\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — review article synthesizing prior experimental data; no new primary experiments reported\",\n      \"pmids\": [\"29175460\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BAD is a BH3-only pro-apoptotic BCL-2 family member that is held inactive through phosphorylation at multiple serine residues (Ser-112, Ser-136, Ser-155 in mouse; S75, S99, S118 in human) by survival kinases including Akt (downstream of IL-3/PI 3-kinase), PKA, and RSK1; phosphorylation at Ser-112/136 sequesters BAD to cytoplasmic 14-3-3 proteins, while phosphorylation at Ser-155 within the BH3 domain directly blocks heterodimerization with BCL-XL, and unphosphorylated BAD localizes to mitochondria where it binds BCL-2/BCL-XL to promote apoptosis; BAD is also dephosphorylated/activated downstream of the TSC2 tumor suppressor, and beyond apoptosis BAD participates in regulating glucose metabolism at the mitochondria.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BAD is a BH3-only pro-apoptotic BCL-2 family member that couples survival-kinase signaling to the mitochondrial apoptotic machinery, with its activity gated by multisite serine phosphorylation [#0, #3, #4]. In its unphosphorylated state, BAD localizes to mitochondria and heterodimerizes with the anti-apoptotic proteins BCL-2 and BCL-XL to promote cell death, whereas phosphorylation sequesters it away from mitochondria via 14-3-3 binding and neutralizes its death-promoting function [#3]. Survival signaling enforces this inhibition through several kinases: Akt phosphorylates BAD downstream of IL-3/PI 3-kinase to block its pro-apoptotic activity [#0], while PKA and RSK1 phosphorylate Ser-155 within the BH3 domain to directly disrupt BAD–BCL-XL binding, a mechanism distinct from the Ser-112/Ser-136 phosphorylation that drives 14-3-3 sequestration [#1]. Conversely, the TSC2 tumor suppressor activates BAD by reducing Ser-136 phosphorylation through downregulation of p70S6K, increasing BAD/BCL-2 and BAD/BCL-XL heterodimerization to promote apoptosis [#2]. The balance of BAD phosphorylation (human S75, S99, S118) sets the pro-apoptotic versus pro-survival output, and dephosphorylation by PP2C-class phosphatases opposes the survival state; elevated phospho-BAD confers a growth advantage in cancer cells [#5]. Beyond apoptosis, BAD participates in non-apoptotic functions including the regulation of mitochondrial glucose metabolism [#3].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"Established that survival signaling directly inactivates the death machinery by identifying Akt as the kinase that phosphorylates BAD downstream of IL-3/PI 3-kinase, linking growth-factor signaling to apoptosis suppression.\",\n      \"evidence\": \"In vitro kinase reconstitution plus in vivo phosphorylation analysis with PI 3-kinase inhibitors in IL-3-stimulated cells\",\n      \"pmids\": [\"9381178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Did not resolve how phosphorylation translates to subcellular relocalization away from mitochondria\",\n        \"Other survival kinases acting on BAD not yet mapped\"\n      ]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Resolved that BAD inhibition occurs through two mechanistically distinct phosphorylation modes, showing that Ser-155 phosphorylation within the BH3 domain directly blocks BCL-XL binding, separate from the Ser-112/Ser-136 sites that drive 14-3-3 sequestration.\",\n      \"evidence\": \"In vitro kinase assay, co-immunoprecipitation, site-directed mutagenesis, and cell death rescue assays with PKA and RSK1\",\n      \"pmids\": [\"10837486\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relative contribution of each site to physiological survival signaling not quantified\",\n        \"Structural basis of BH3-domain phosphorylation blocking heterodimerization not determined\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Placed BAD genetically as the connector between survival kinase signaling and the apoptotic machinery in vivo, validating its pathway position across model organisms.\",\n      \"evidence\": \"Genetic epistasis and in vivo studies in Drosophila and mammals\",\n      \"pmids\": [\"12431365\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Commentary-level synthesis rather than a single primary mechanistic dataset\",\n        \"Did not define tissue-specific kinase inputs\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Identified an upstream activator of BAD by showing the TSC2 tumor suppressor reduces Ser-136 phosphorylation via p70S6K downregulation and increases BAD/BCL-2 and BAD/BCL-XL heterodimerization to drive apoptosis.\",\n      \"evidence\": \"BAD-/- cell experiments, reciprocal co-immunoprecipitation, phosphorylation analysis, and TSC2 overexpression/knockdown\",\n      \"pmids\": [\"16702951\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Phosphatase mediating the Ser-136 dephosphorylation not identified\",\n        \"Single-lab study with limited cell-type breadth\"\n      ]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Linked the BAD phosphorylation state to cancer cell survival by showing phospho-BAD is elevated in cancer cells and that PP2C depletion further raises phospho-BAD and confers a growth advantage.\",\n      \"evidence\": \"siRNA depletion of PP2C, MTS proliferation assays, immunofluorescence for phospho-BAD, RT-qPCR\",\n      \"pmids\": [\"25653146\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Direct phosphatase–substrate relationship between PP2C and BAD not biochemically reconstituted\",\n        \"Specific PP2C isoform and target residues not pinpointed\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Consolidated the model that three serine phosphosites (S75, S99, S118) toggle BAD between pro-apoptotic and pro-survival functions, including non-apoptotic roles in glycolysis, autophagy, and cell cycle.\",\n      \"evidence\": \"Review synthesizing prior in vitro and in vivo phosphorylation studies\",\n      \"pmids\": [\"29175460\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Review without new primary experiments\",\n        \"Molecular mechanisms underlying the non-apoptotic glycolytic and autophagy roles not detailed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How BAD mechanistically coordinates mitochondrial glucose metabolism with the apoptotic decision, and which phosphatases physiologically reactivate BAD, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No reconstituted mechanism connecting BAD phosphorylation to metabolic enzyme activity\",\n        \"Physiological phosphatase(s) reactivating BAD in vivo not definitively established\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 3, 4]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"BCL2\", \"BCL2L1\", \"AKT1\", \"RSK1\", \"PRKACA\", \"TSC2\", \"YWHAZ\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":6,"faith_pct":83.33333333333333}}